Related Experiment Videos

WldS mice are resistant to paclitaxel (taxol) neuropathy

Min Sheng Wang1, Albert A Davis, Deborah G Culver

  • 1Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.

Annals of Neurology
|September 27, 2002
PubMed

Insights

The WldS mouse, exhibiting slow Wallerian degeneration, shows resistance to paclitaxel-induced peripheral neuropathy. This highlights a protective mechanism against axonal degeneration, offering insights for neurological disorder prevention.

Area of Science:

  • Neuroscience
  • Genetics
  • Toxicology

Background:

  • The WldS mouse model exhibits prolonged axonal survival after transection, a phenomenon termed slow Wallerian degeneration.
  • Axonal degeneration is a key pathological feature in various peripheral neuropathies.

Purpose of the Study:

  • To investigate if the neuroprotective phenotype of WldS mice extends to paclitaxel-induced peripheral neuropathy.
  • To explore the mechanistic link between Wallerian degeneration and chemotherapy-induced axonal damage.

Main Methods:

  • WldS and wild-type mice were administered paclitaxel (Taxol) to induce sensory neuropathy.
  • Neuropathy severity was assessed using behavioral, physiological, and pathological evaluations.

Main Results:

  • WldS mice demonstrated significant resistance to paclitaxel-induced neuropathy across all measured parameters.
  • This resistance was attributed to the WldS mutation conferring protection against axonal degeneration.

Conclusions:

  • The WldS mouse model offers a valuable tool for studying mechanisms underlying peripheral neuropathy beyond Wallerian degeneration.
  • Understanding the WldS neuroprotective mechanism may provide therapeutic strategies for preventing axonal degeneration in human neurological diseases.

Related Concept Videos